JP Morgan discloses Kangji Medical shares dealings amid privatization bid

The Securities and Futures Commission (SFC) announced on October 9, 2025, that J.P. Morgan Securities PLC, an associate connected with the offeror, has disclosed dealings in Kangji Medical Holdings Limited shares. These transactions are part of a privatization effort via a scheme of arrangement, as per Rule 22 of the Hong Kong Code on Takeovers and Mergers.

On October 8, 2025, J.P. Morgan Securities PLC executed both sales and purchases of Kangji Medical shares for its own account. The sales involved 3,500 shares for a total of $31,112.23, with prices ranging from a high of $8.93 to a low of $8.87. Concurrently, J.P. Morgan purchased 438,500 shares for a total of $3,917,708.23, with both the highest and lowest prices recorded at $8.93.

These dealings were primarily for hedging Delta 1 products, which resulted from wholly unsolicited client-driven orders, and relate to equity swaps. J.P. Morgan Securities PLC is ultimately owned by JPMorgan Chase & Co.